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Summary 
Background Progesterone administration has been shown to reduce the risk of preterm 
birth and neonatal morbidity in women at high risk, but there is uncertainty about longer 
term effects on the child.  
Methods We did a double-blind, randomised, placebo-controlled trial of vaginal 
progesterone, 200 mg daily taken from 22–24 to 34 weeks of gestation, on pregnancy and 
infant outcomes in women at risk of preterm birth (because of previous spontaneous birth 
at ≤34 weeks and 0 days of gestation, or a cervical length ≤25 mm, or because of a positive 
fetal fibronectin test combined with other clinical risk factors for preterm birth [any one of a 
history in a previous pregnancy of preterm birth, second trimester loss, preterm premature 
fetal membrane rupture, or a history of a cervical procedure to treat abnormal smears]). 
The objective of the study was to determine whether vaginal progesterone prophylaxis 
given to reduce the risk of preterm birth affects neonatal and childhood outcomes. We 
defined three primary outcomes: fetal death or birth before 34 weeks and 0 days gestation 
(obstetric), a composite of death, brain injury, or bronchopulmonary dysplasia (neonatal), 
and a standardised cognitive score at 2 years of age (childhood), imputing values for deaths. 
Randomisation was done through a web portal, with participants, investigators, and others 
involved in giving the intervention, assessing outcomes, or analysing data masked to 
treatment allocation until the end of the study. Analysis was by intention to treat. This trial 
is registered at ISRCTN. com, number ISRCTN14568373.  
Findings Between Feb 2, 2009, and April 12, 2013, we randomly assigned 1228 women to 
the placebo group (n=610) and the progesterone group (n=618). In the placebo group, data 
from 597, 587, and 439 women or babies were available for analysis of obstetric, neonatal, 
and childhood outcomes, respectively; in the progesterone group the corresponding 
numbers were 600, 589, and 430. After correction for multiple outcomes, progesterone had 
no significant effect on the primary obstetric outcome (odds ratio adjusted for multiple 
comparisons [OR] 0·86, 95% CI 0·61–1·22) or neonatal outcome (OR 0·62, 0·38–1·03), nor on 
the childhood outcome (cognitive score, progesterone group vs placebo group, 97·3 [SD 
17·9] vs 97·7 [17·5]; difference in means –0·48, 95% CI –2·77 to 1·81). Maternal or child 
serious adverse events were reported in 70 (11%) of 610 patients in the placebo group and 
59 (10%) of 616 patients in the progesterone group (p=0·27).  
Interpretation Vaginal progesterone was not associated with reduced risk of preterm birth 
or composite neonatal adverse outcomes, and had no long-term benefit or harm on 
outcomes in children at 2 years of age.  
Funding Efficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council 
(MRC) and National Institute for Health Research (NIHR) partnership. The EME Programme 
is funded by the MRC and NIHR, with contributions from the Chief Scientist Office in 
Scotland and National Institute for Social Care and Research in Wales.  
Introduction  
Several studies have assessed either vaginal progesterone or intramuscular 17α-
hydroxyprogesterone caproate for the prevention of preterm birth in asymptomatic women 
with singleton pregnancy at high risk of preterm birth. An individual patient data meta-
analysis of women with a short cervix showed that vaginal progesterone reduced the risk of 
preterm birth before 33 weeks (relative risk [RR] 0·58, 95% CI 0·42–0·80) and reduced a 
composite of neonatal mortality and morbidity (RR 0·57, 0·40–0·81) Although there is 
debate whether vaginal  
and intramuscular therapies have similar mechanisms or efficacy, the Cochrane Library 
meta-analysis groups the two treatments together, but reports separately for different 
maternal risk groups.2 Reduced risk of preterm birth before 34 weeks was shown in women 
with a short cervix (RR 0·64, 95% CI 0·45–0·90), without effect on perinatal mortality or 
neonatal death (perinatal mortality RR 0·74, 0·42–1·29; neonatal death RR 0·55, 0·26–
1·13By contrast, in women with previous preterm birth, progestogens reduced the 
incidence of preterm birth (RR 0·31, 95% CI 0·14–0·69), perinatal  
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Research in context  
Evidence before this study  
Vaginal progesterone administration has been shown to reduce the risk of preterm birth 
and neonatal morbidity in women at high risk, but there is uncertainty about longer term 
effects on the child. We searched the Cochrane Pregnancy and Childbirth Group’s Trials 
Register and the Cochrane Central Register of Controlled Trials (the Cochrane Library) until 
Feb 4, 2016, on MEDLINE (Jan 1, 1996, to Feb 4, 2016), and PubMed (Jan 1, 1974, to Feb 4, 
2016) using the terms “progesterone/ progestogen” AND “preterm birth prevention” AND 
“randomised trial” with no language restrictions. We also searched reference lists of trials 
and other review articles identified from this initial search and from our records. We 
excluded women with multiple pregnancy and those with symptoms of preterm labour. We 
identified two systematic reviews that compared preterm birth rates, neonatal outcomes, 
or childhood outcomes in women treated with progesterone or progestogens compared 
with those treated with placebo: a conventional meta-analysis published by the Cochrane 
collaboration and an individual patient data meta-analysis. No additional randomised trials 
were identified which were not included in the Cochrane review. Neither of the meta-
analyses reported on our three primary outcomes, those of fetal death or delivery, either 
occurring before 34 weeks and 0 days of gestation (obstetric primary outcome); a composite 
of death, bronchopulmonary dysplasia, and brain injury on cerebral ultrasound (neonatal 
primary outcome); or the Bayley-III cognitive composite score at 22–26 months of 
chronological age (childhood primary outcome). One individual patient data meta-analysis 
of women with a short cervix reported the effect of vaginal progesterone on the outcomes 
of preterm birth before 33 weeks (relative risk [RR] 0·58, 95% CI 0·42–0·80), and on a 
composite of neonatal mortality and morbidity (RR 0·57, 0·40–0·81). This individual patient 
data meta-analysis was restricted to women treated with vaginal progesterone. The 
Cochrane Library meta-analysis grouped women treated with any progestogen and reported 
on risk of preterm birth before  
34 weeks review for women with a short cervix (RR 0·64, 95% CI 0·45–0·90), and on 
perinatal mortality (RR 0·74, 0·42–1·29) or neonatal death (RR 0·55, 0·26–1·13). Regarding 
women with a  
previous preterm birth, the Cochrane Library reported that progestogens reduced the 
incidence of preterm birth (RR 0·31, 95% CI 0·14–0·69), and both perinatal mortality (RR 
0·50, 0·33–0·75) and neonatal death (RR 0·45, 0·27–0·76). Neither the individual patient 
data meta-analysis nor the Cochrane review were able to report on childhood outcomes, 
with the Cochrane review noting that “there is limited information available relating to 
longer-term infant and childhood outcomes, the assessment of which remains a priority”.  
Added value of this study  
The OPPTIMUM study is, to our knowledge, the largest study to compare obstetric, 
neonatal, and childhood outcomes in high-risk women with singleton pregnancy treated 
with vaginal progesterone to prevent preterm birth. It is one of the few studies to look at 
childhood effects. In OPPTIMUM, by contrast with some of the published literature, vaginal 
progesterone was not significantly associated with reduced risk either of preterm birth or of 
composite neonatal adverse outcomes. Additionally, progesterone had no significant long-
term benefit or harm on outcomes in children at 2 years of age. The primary outcomes 
reported in OPPTIMUM were different from the outcomes reported in the meta-analyses 
described above (and indeed different from the primary outcomes in the source studies), 
hence meta-analysis of the evidence to provide a meaningful pooled estimate was not 
possible. We plan an individual patient data level analysis that will be able to address 
complexities such as different inclusion criteria for the studies, different progestogens used 
(vaginal progesterone or 17α-hydroxyprogesterone caproate), and the differences in 
outcome reporting.  
Implications of all the available evidence  
The findings from OPPTIMUM are different to some of those reported in the literature. For 
the first time, we show childhood outcomes of progesterone to prevent preterm birth. The 
results of OPPTIMUM should prompt a major review of the use of progesterone for preterm 
birth prophylaxis, a search to identify specific women who might specifically benefit, and a 
redoubling of efforts to find alternative strategies to prevent preterm birth in women at 
risk.  
mortality and neonatal death.2 Although intramuscular 17α-hydroxyprogesterone caproate 
is licensed for women with a previous preterm birth, an independent analysis of data on 
vaginal progesterone for a US Food and Drug Administration advisory panel showed no 
benefit, with the panel concluding that “the overall risk/benefit profile [is] not acceptable” 
to support approval of vaginal progesterone in women with a short cervix. 
Despite recommendations for progesterone use there are few data on long-term benefit or 
safety for the baby beyond the neonatal period. Adverse childhood effects of preterm birth 
include neurodevelopmental and cognitive impairments, and increase with degree of 
prematurity. 
Progesterone, by delaying birth and reducing prematurity, might reduce risk of impairment, 
but this could be offset by direct fetal harm by continuing prolonged exposure to 
intrauterine infection or inflammation, commonly associated with preterm labour. 
Furthermore, therapies applied in pregnancy might have differing effects in the neonatal 
period and early childhood (benefit in one and harm in another), as shown in the ORACLE II 
trial of antibiotics in spontaneous preterm labourand in trials of multiple doses of 
corticosteroids. Hence, further information on childhood outcomes following progesterone 
treatment is required to determine the risk–benefit ratio of this therapy.  
Therefore, we did a double-blind randomised trial to determine whether vaginal 
progesterone prophylaxis given to reduce the risk of preterm birth affects neonatal and 
childhood outcomes.  
Methods  
Study design and participants  
OPPTIMUM (dOes Progesterone Prophylaxis To prevent preterm labour IMprove oUtcoMe?) 
is a multicentre randomised double-blind placebo-controlled trial. Women were recruited 
from 65 UK National Health Service hospitals and one Swedish hospital. An abbreviated 
protocol has been published.  
The study was granted approval by the Scotland A Research Ethics Committee (reference 
08/MRE00/6). Clinical trials authorisation was given by the Medicines and Healthcare 
products Regulatory Agency (MHRA reference 22931/0009/001-0001 later revised to 
01384/0208/001). A trial steering committee and a Data Monitoring Committee supervised 
the conduct of the study (appendix).  
The study comprised a screening phase at 18–24 weeks and 0 days gestation and a 
treatment phase, starting at between 22 and 24 weeks of gestation. Written informed 
consent was obtained for both the screening phase (at 18–24 weeks and 0 days gestation) 
and treatment phase (between 22 and 24 weeks gestational age). All women had a 
singleton pregnancy, with gestational age established by ultrasound scan before 16 weeks, 
and were 16 years or older at screening. Women with clinical risk factors for preterm birth 
(any of a history in a previous pregnancy of preterm birth, or second trimester loss, or 
preterm premature fetal membrane rupture, or any history of a cervical procedure to treat 
abnormal smears) and a positive fetal fibronectin test at 22–24 weeks of gestation were 
eligible for random allocation in the treatment phase from the beginning of the trial, and 
designated fibronectin positive. After analysis of preliminary (masked) data in July, 2010, 
and the publication of a systematic review on screening for preterm birth, we realised that 
our initial selection strategy erroneously missed women at medium-to-high risk of preterm 
birth. Thus, from Sept 1, 2010, after recruitment of the initial 84 women, fibronectin-
negative women with a history of spontaneous preterm birth at 34 weeks or less of 
gestation, or a cervical length of 25 mm or less were also eligible for inclusion, and 
designated a fibronectin-negative group (see appendix for detailed inclusion and exclusion 
criteria and fibronectin-positive or fibronectin-negative group allocation). There are no 
nationally agreed recommendations on which pregnant women should be screened for 
preterm birth risk by measuring cervical length, nor did the OPPTIMUM protocol include 
recommendations on who should undergo cervical length screening, hence any such 
measurements were made by clinicians on an individual patient basis before the woman’s 
recruitment to OPPTIMUM. A cervical  
length of 25 mm or less at any time between 18 and 24 weeks and 0 days gestation in the 
index pregnancy conferred eligibility for recruitment.  
Randomisation and masking  
Eligible women were allocated (1:1) to either progesterone 200 mg soft capsules 
(Utrogestan, Besins Healthcare) or an identical appearing placebo. Assignment to treatment 
allocation was done through a web portal hosted by the study data centre at the Robertson 
Centre for Biostatistics, at the Glasgow Clinical Trials Unit, University of Glasgow. The 
randomisation schedule was computer-generated at the Robertson Centre, using the 
method of randomised permuted blocks of length four, stratified by history of a previous 
pregnancy of more than 14 weeks of gestation and by study centre. Allocation concealment 
was achieved by use of a placebo, which appeared identical to the active drug. Participants 
were asked for informed consent and enrolled by collaborating clinicians (listed in this 
Article and the appendix), who used the web portal described above to randomly assign 
participants to treatment. Treatment allocation corresponded to a box number in the local 
pharmacy, containing either active or placebo drug. Participants, investigators, pharmacists, 
and others involved in giving the intervention, assessing outcomes, or analysing data 
remained masked to treatment allocation until the end of the study. There was no formal 
attempt made to assess the success of masking.  
Procedures  
The participant administered the vaginal study medication daily at bedtime, commencing 
from about 22–24 weeks of gestationuntil34weeksordeliveryofthebaby,whichever was 
sooner. Co-administration of bromocriptine, rifamycin, 
ketoconazole,orciclosporinwasprohibitedduetopotential drug interactions. Rules for 
individual women to stop treatment on safety grounds (eg, after development of 
symptomaticplacentapraevia)aredefinedintheprotocol.  
Compliance (assessed for each woman using a combination of medication pack returns, 
patient diaries, and patient self-reports) was calculated as the percentage of doses of study 
medication used divided by the expected doses. Adequate compliance was taken as 80% of 
prescribed medication.  
Data were collected at screening, randomisation, 34 weeks 
ofgestation,duringlabouranddelivery,duringtheneonatal stayandat1and2yearspost-
deliverytodetermineclinical outcomes.2yearassessments,basedonchronologicalage because 
of the mixed term and preterm population, were done at the local hospital clinic or at 
home. This assessment comprisedtheparent-completedstructuredclinicalhistory, a parent-
completed behavioural measure (the Strengths and Difficulties Questionnaire) and the 
cognitive scale of the Bayley Scales of Infant and Toddler Development 3rd Edition (Bayley-
III). All assessments were undertaken by  
assessors who had received training, either from the study centre or via a national course; 
all met prespecified criteria of 90% agreement or more on an item-by-item basis with an 
independent psychologist. Record forms were checked centrally for consistency and 
completeness. For children for whom we could not arrange a clinic assessment we 
requested information from the family doctor concerning general health and the presence 
of motor, sensory, and developmental concerns.  
Outcomes  
We defined three primary outcomes: either fetal death or delivery occurring before 34 
weeks and 0 days of gestation (obstetric outcome); a composite of death, broncho- 
pulmonary dysplasia, and brain injury on cerebral ultrasound (neonatal outcome); and the 
Bayley-III cognitive composite score at 22–26 months of chronological age (childhood 
outcome).  
Brain injury was defined as any intraventricular haemorrhage (excluding subependymal 
haemorrhages), parenchymal cystic lesion or haemorrhagic lesion, or persistent 
ventriculomegaly (ventricular index >97th percentile). All scans were reported locally. All 
abnormal scans and 10% of normal scans were reviewed centrally masked to the local 
report (NM). Bronchopulmonary dysplasia (severe chronic lung disease) was defined as 
need for at least 30% oxygen or positive pressure (positive pressure ventilation or nasal 
continuous positive airway pressure) at 36 weeks postmenstrual age or discharge, 
whichever came first.  
Secondary efficacy and safety outcomes were as follows: gestational age at delivery 
(weeks); deaths up to 2 years of age; death after trial entry up to the end of study; daily 
category of care after delivery room (normal or special or high dependency or intensive); 
surfactant administration; suspected or confirmed necrotising entercolitis; neonatal 
infections (one or more discrete episodes with positive blood culture among those with 
infection, one or more discrete episodes with positive CNS culture among those with 
infection); maternal or child serious adverse events during pregnancy and birth; composite 
outcome of death or moderate-to-severe neurodevelopmental impairment at 2 years; 
moderate-to-severe neurodevelopmental impair- ment; individual components of disability; 
admissions to hospital during follow-up; behavioural scale scores at 2 years assessed in 
strengths and difficulties questionnaire; change in EuroQol 5D (EQ-5D) from baseline to 
birth; change in EQ-5D from baseline to 12 months; and women’s perception of treatment 1 
month post-delivery (the proportion extremely or fairly satisfied). Outcomes were 
categorised as moderate or severe using published definitions. 
Statistical analysis  
A statistical analysis plan was finalised before data lock. Statistical analyses were done by C-
MM and AM at the Robertson Centre for Biostatistics, Glasgow University  
Figure: Trial profile 
*Randomised in error, ineligible for treatment, and excluded post-randomisation. †Consent 
withdrawals for each of the phases refer to consent withdrawal at any time before reaching 
the outcome for that phase. ‡Losses to follow-up for each of the phases refer to losses to 
follow-up at any time before reaching the outcome for that phase. §Numbers with missing 
outcome data refer to each specific outcome only (obstetric, neonatal, and childhood) and 
are not additive across the stages since women can have outcome data for a later outcome.  
according to the intention-to-treat principle. The three primary outcomes and secondary 
outcomes were compared between the treatment groups using mixed  
Articles  
15 132 patient records assessed for eligibility  
5833 eligible women tested with fibronectin in the screening phase  
8724 excluded from eligibility screening visit 1540 not approached  
6014 declined to participate before screening visit 1170 failed to attend eligibility screening 
visit  
6408 attended eligibility screening visit  
575 excluded from fibronectin test screening phase 510 declined participation  
53 ineligible 
12 did not have fibronectin test  
1228 patients randomly assigned  
4605 excluded from randomisation 
3461 ineligible (negative fibronectin, no other  
risk factor) 
1144 eligible but not randomly assigned  
610 allocated to placebo 
181 fibronectin positive 429 fibronectin negative  
618 allocated to progesterone 163 fibronectin positive 453 fibronectin negative  
2 unknown fibronectin status  
42 withdrew consent after initiating treatment† 10 obstetric  
8 neonatal 
24 childhood 100 lost to follow-up‡ 2 obstetric 
1 neonatal 
97 childhood  
1 missing obstetric outcome data only§  
2 missing neonatal outcome data only§  
29 missing childhood outcome data only§  
2 withdrawn before initiating treatment*  
45 withdrew consent after initiating treatment†  
10 obstetric 3 neonatal 32 childhood  
116 lost to follow-up‡ 6 obstetric  
110 childhood 
8 missing neonatal outcome  
data only§ 
25 missing childhood outcome  
data only§  
597 analysed in the obstetric phase 587 analysed in the neonatal phase 439 analysed in the 
childhood phase  
600 analysed in the obstetric phase 589 analysed in the neonatal phase 430 analysed in the 
childhood phase  
2109  
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Placebo group  
N n (%) or mean (SD) 610 31·4 (5·8)  
609 34 (6%) 568 13·5 (3·0)  
607 163·6 (6·4) 607 26·7 (6·1) 608 66·2 (8·6) 609 571 (94%) 598 448 (75%)  
609 48 (8%) 351 28·8 (11·1) 351 119 (34%) 351 47 (13%)  
Progesterone group  
Age (years) 
Alcohol 
Years in full-time education  
Height (cm) 
Body-mass index (kg/m2) 
Diastolic blood pressure (mm Hg) Previous pregnancy of at least 14 weeks History of 
spontaneous preterm birth  
History of stillbirth Cervical length  
Cervical length ≤25 mm Cervical length ≤15 mm  
N 615  
614 554  
614 614 611 615 605  
615 361 361 361  
n (%) or mean (SD) 31·5 (5·6)  
29 (5%) 13·5 (3·1)  
163·5 (6·7) 26·9 (6·4) 65·7 (8·5)  
578 (94%) 473 (78%)  
47 (8%)  
28·2 (10·6) 137 (38%) 51 (14%)  
Smoking  607  125 (21%)  613  111 (18%)  
 
Drug use  609  9 (1%)  614  8 (1%)  
 
Ethnic group      
White  609  446 (73%)  615  449 (73%)  
Black  609  95 (16%)  615  85 (14%)  
Asian  609  51 (8%)  615  53 (9%)  
Mixed  609  12 (2%)  615  16 (3%)  
Other  609  5 (1%)  615  12 (2%)  
 
Weight (kg)  607  71·4 (16·7)  614  71·9 (17·5)  
 
Systolic blood pressure (mm Hg)  608  112·4 (12·2)  611  111·3 (12·5)  
 
Any previous pregnancy  609  581 (95%)  615  591 (96%)  
 
History of preterm birth (any)  608  473 (78%)  615  493 (80%)  
 
History of livebirth followed by neonatal death  609  85 (14 %)  615  80 (13%)  
 
Fibronectin testing in screening phase      
Gestation (weeks) at fibronectin test  610  22·9 (0·6)  615  22·9 (0·6)  
Positive fibronectin test result  610  180 (30%)  615  163 (27%)  
Continuous variables are mean (SD), categorical variables are n (%).  
Table 1: Demographics and baseline characteristics of women entered into the treatment 
phase of the OPPTIMUM study  
2110 www.thelancet.com Vol387 May21,2016  
effects logistic regression (or, for continuous variables, linear regression) models including 
treatment allocation and previous pregnancy (≥14 weeks) as fixed effects, with study centre 
as a random effect. According to the prespecified statistical analysis plan, p values were 
initially reported without adjustment for multiple comparisons, then adjusted using a 
Bonferroni-Holm procedureThe planned sample size was around 1125 participants, 
depending on the relative numbers of fetal fibronectin- positive and fetal fibronectin-
negative women recruited. 
Detailedsamplesizecalculationsareavailableinthe published protocol, but in brief the study 
had at least 80% power to detect what was considered the minimal important clinical 
difference for each of the three primary outcomes at a nominal 5% level of significance. 
Sensitivity analyses included repeating the primary analyses in a per-protocol dataset (which 
excluded data from women who were found not to be compliant with the inclusion or 
exclusion criteria, or who had a structural or  
chromosomal fetal anomaly discovered after inclusion, or who had a multiple pregnancy 
discovered after inclusion or who were not adequately compliant with treatment by the 
prespecified definition), and the use of multiple imputation of missing primary outcome 
data. Preplanned subgroup analyses for primary outcomes were done by extending the 
main regression models to include interaction terms for the following subgroups: 
fibronectin positive or fibronectin negative, cervical length of at most 25 mm or longer than 
25 mm, cervical length of at most 15 mm or longer than 15 mm, chorioamnionitis yes or no, 
history of spontaneous preterm birth or no such history, and history of preterm birth or no 
such history. Safety outcomes (adverse events) were assessed in a safety population, 
excluding women for whom it was documented that no study medication was taken. This 
trial is registered with ISRCTN.com, number ISRCTN14568373.  
Role of the funding source  
Neither the funders of the study nor the provider of active and placebo medication had any 
role in study design, data collection, data analysis, data interpretation, or writing of the 
report. C-MM and AM had full access to all the data in the study and JEN had final 
responsibility for the decision to submit for publication.  
Results  
We reviewed the case notes of 15 132 women for eligibility, between Feb 2, 2009, and April 
12, 2013. 1228 (8%) were subsequently randomly assigned, 610 allocated to placebo and 
618 to progesterone (figure). Two of these women were randomised in error and were 
excluded from initiating on treatment and the intention-to-treat population. Baseline 
characteristics of participants in the intention-to-treat population were balanced across the 
two allocated groups (table 1). The number of women randomly assigned per site ranged 
from one to 165; three sites screened but did not randomly assign participants. Information 
on the obstetric, neonatal, and childhood primary outcomes was available for 1197 (97%), 
1176 (96%), and 869 (71%) of participants, respectively. There were few differences in 
baseline characteristics between those for whom primary outcome data was or was not 
available (appendix).  
Information from diary returns for 1011 (82%) women showed 80% or more compliance in 
361 (71%) of 509 in the placebo group and 333 (66%) of 502 in the progesterone group. For 
compliant women, the median percentage of medication taken was 92·3% (IQR 71·6–98·7) 
and 92·9% (59·0–98·6), respectively. No woman terminated treatment because of 
prespecified discontinuation rules.  
Although the point estimate of the odds ratio (OR) was in the direction of benefit, 
administration of progesterone did not significantly alter the risk of the obstetric (fetal 
death or birth before 34 weeks) or neonatal (a composite of death, brain injury, or 
bronchopulmonary dysplasia)  
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Fetal death or delivery <34 weeks of gestation Cognitive composite score at 2 years†‡  
Components of the neonatal outcome Neonatal death 
Bronchopulmonary dysplasia|| Brain injury on ultrasound scan**  
Placebo group  
108/597 (18%) 97·7 (17·5)  
6/597 (1%) 18/574 (3%) 34/574 (6%)  
Progesterone group  
96/600 (16%) 97·3 (17·9)  
1/600 (<1%) 17/580 (3%) 18/584 (3%)  
Unadjusted odds ratio (95% CI) or difference in means (95% CI)  
0·86 (0·64 to 1·17) –0·48 (–2·77 to 1·81)§  
0·17 (0·06 to 0·49) 0·94 (0·49 to 1·78) 0·50 (0·31 to 0·84)  
p value (unadjusted)  
0·34 0·68  
0·0009¶ 0·84 0·008  
Adjusted odds ratio (95% CI)* or difference in means (95% CI)  
0·86 (0·61 to 1·22) –0·48 (–2·77 to 1·81)§  
·· ·· ··  
p value (adjusted*)  
0·67 0·68  
·· ·· ··  
Neonatal morbidity or 
death  
60/587 
(10%)  
39/589 
(7%)  
0·62 (0·41 to 
0·94)  
0·02  
0·62 (0·38 to 
1·03)  
0·072  
 
Components of the obstetric 
outcome  
      
Fetal death  7/597 (1%)  8/600 (1%)  
1·14 (0·41 to 
3·17)  
0·8  ··  ··  
Liveborn delivery before 34 weeks  
101/590 
(17%)  
88/592 
(15%)  
0·85 (0·62 to 
1·15)  
0·29  ··  ··  
Binary outcomes are n/N (%) and continuous outcomes are mean (SD). *CI for odds ratio 
(OR) and p value adjusted for multiple primary outcomes using Bonferroni-Holm method. 
†Median weeks of age at assessment: 111·6 weeks (IQR 104·6–122·2) in the placebo group 
and 110·4 weeks (104·0–121·5) in the progesterone group. ‡Sample size of 439 in the 
placebo group and 430 in the progesterone group and includes imputations for deaths. 
§Difference in means (95% CI). ¶Unadjusted for previous pregnancy of at least 14 weeks 
because of small sample size. ||Bronchopulmonary dysplasia defined as need for at least 
30% oxygen to maintain oxygen saturation above 92% or positive pressure (positive 
pressure ventilation or nasal continuous positive airway pressure) at 36 weeks 
postmenstrual age or discharge, whichever comes first. **Brain injury on ultrasound scan 
defined as any intraventricular haemorrhage (excludes subependymal haemorrhages), 
parenchymal cystic or haemorrhagic lesion, or persistent ventriculomegaly (ventricular 
index >97th percentile); the components of the brain scan abnormalities were: 
intraventricular haemorrhage 13 (3%) of 383 patients and seven (2%) of 357 patients, 
parenchymal cystic or haemorrhagic lesion 23 (6%) of 382 and eight (2%) of 357, and 
persistent ventriculomegaly (>97th percentile) eight (2%) of 372 and three (1%) of 349 in 
the placebo group and the progesterone group, respectively.  
Table 2: Primary outcomes and their components for women entered into the treatment 
phase of the OPPTIMUM study and their babies  
Fibronectin status Obstetric outcome Neonatal outcome Childhood outcome  
Cervical length at baseline Obstetric outcome Neonatal outcome Childhood outcome  
History of spontaneous preterm birth Obstetric outcome 
Neonatal outcome 
Childhood outcome  
Treatment effect  
OR or mean difference (95% CI); p value  
Negative 
0·88 (0·58 to 1·33); 0·542 0·65 (0·37 to 1·13); 0·129  
–0·63* (–3·28 to 2·03); 0·644  
>15 mm 
0·77 (0·48 to 1·23); 0·274 0·73 (0·39 to 1·38); 0·334  
–2·49* (–5·77 to 0·78); 0·137  
No 
0·99 (0·51 to 1·92); 0·972 1·22 (0·55 to 2·71); 0·620  
–1·11* (–5·96 to 3·73); 0·653  
N   
Negative 859 
847 
628  
>15 mm 599 588 423  
No 273 270 201  
OR or mean difference (95% CI); N p value  
Positive Positive 0·91 (0·57 to 1·46); 0·707 338 0·64 (0·34 to 1·20); 0·162 329  
–1·09* (–5·41 to 3·23); 0·612 241  
≤15 mm ≤15 0·91 (0·41 to 2·04); 0·819 97 0·49 (0·18 to 1·31); 0·156 94  
–0·69* (–8·60 to 7·22); 0·865 73  
Yes Yes 0·82 (0·58 to 1·16); 0·254 903 0·48 (0·29 to 0·79); 0·0042 886  
–0·14* (–2·79 to 2·52); 0·919 656  
pinteraction   
0·91 0·96 0·86  
Cervical length at 
baseline  
>25 mm  
>25 
mm  
≤25 mm  
≤25 
mm  
 
Obstetric outcome  
0·88 (0·50 to 1·57); 
0·672  
445  
0·69 (0·39 to 1·20); 
0·191  
251  0·54  
Neonatal outcome  
0·74 (0·35 to 1·56); 
0·432  
436  
0·54 (0·25 to 1·16); 
0·113  
246  0·56  
Childhood outcome  
–2·27* (–6·10 to 1·56); 
0·247  
317  
–2·15* (–7·23 to 2·93); 
0·408  
179  0·97  
mm 
0·73  
0·50 0·68  
0·62 0·053 0·73  
Chorioamnionitis  No  No  Yes  Yes   
Obstetric outcome  1·38 (0·55 to 3·45); 0·497  115  2·17 (0·68 to 6·85); 0·190  57  0·55  
Neonatal outcome  0·81 (0·22 to 2·96); 0·752  115  2·21 (0·76 to 6·40); 0·148  56  0·24  
Childhood 
outcome  
–2·30* (–10·30 to 5·70); 
0·575  
81  
–1·08* (–11·91 to 9·76); 
0·846  
43  0·86  
 
History of any preterm 
birth  
No  No  Yes  Yes   
Obstetric outcome  1·06 (0·53 to 2·12); 0·868  250  0·81 (0·58 to 1·14); 0·225  946  0·50  
Neonatal outcome  1·09 (0·48 to 2·45); 0·836  248  
0·52 (0·32 to 0·84); 
0·0079  
927  0·12  
Childhood outcome  
–0·91* (–5·92 to 4·11); 
0·724  
187  
–0·37* (–2·96 to 2·23); 
0·782  
681  0·85  
Logistic or linear mixed effects regression models predicting outcome from treatment, 
subgroup and the interaction of treatment with the subgroup variable, adjusting for 
previous pregnancy of at least 14 weeks and a random effect for study centre. *Mean 
difference.  
Table 3: Prespecified subgroup analyses based on baseline risk factors in women entered 
into the treatment phase of the OPPTIMUM study  
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Placebo group Progesterone group OR, HR, or mean p value difference (95% CI)  
N n(%)ormean N n(%)ormean (SD) (SD)  
Obstetric and neonatal  
Gestational age at delivery (weeks)  597  
36·8 (4·2) 
600  
36·9 (4·1) 1·03 
(0·92 to 1·15)  
0·62  
Deaths up to 2 years of age  509  
16 (3%) 
500  
20 (4%) 1·28* 
(0·66 to 2·51)  
0·47  
Death after trial entry up to end of study  598  
16 (3%)† 
600  
20 (3%)† 1·26* 
(0·65 to 2·42)  
0·5  
Daily category of care after delivery room      
Number of days of normal care  570  
1·7 (2·3) 
581  
1·7 (1·6)   
Number of days of special care  570  
4·2 (10·6) 
581  
2·9 (8·3)   
Number of days of high dependency care  569  
2·2 (8·4) 
580  
2·1 (10·4)   
Number of days intensive care  569  
1·8 (7·3) 
580  
1·9 (8·1)   
Surfactant administration  573  
45 (8%) 
583  
47 (8%) 1·03 (0·68 
to 1·55)  
0·9  
Suspected or confirmed necrotising entercolitis  574  
13 (2%) 
581  
18 (3%) 1·37 (0·76 
to 2·45)  
0·29  
Infections      
Neonatal infection  573  
36 (6%) 
537  
44 (8%) 1·22 (0·79 
to 1·88)  
0·36  
One or more discrete episodes with positive blood 
culture among those with infection  
33  
19 (58%) 
40  
17 (42%) 0·51 
(0·19 to 1·34)  
0·18  
One or more discrete episodes with positive CNS 
culture among those with infection  
34  0 40  3(7%) ‡  0·25§  
Maternal or child serious adverse event during 
pregnancy and birth  
610  
70 (11%) 
616  
59 (10%) 0·83 
(0·58 to 1·16)  
0·27  
Childhood (2 years of age)  
Health  
Composite outcome of death or moderate-to-severe neurodevelopmental impairment at 
419 51 (12%) 399 67 (17%) 1·45 (0·98 to 2·15) 0·064 2 years  
Moderate-to-severe neurodevelopmental impairment 403 35 (9%) 379 47 (12%) 1·48 (0·98 
to 2·33) 0·087  
Individual components of disability  
Motor 456 4 (1%) 461 4 (1%) 0·99¶ (0·25 to 3·98) 0·99  
Cognitive function 452 18 (4%) 461 19 (4%) 1·03 (0·58 to 1·84) 0·92  
Hearing 465 2 (<1%) 466 1 (<1%) 0·56¶ (0·33 to 0·94) 0·028  
Speech and language 446 14 (3%) 445 18 (4%) 1·32 (0·72 to 2·43) 0·36  
Vision 466 4 (1%) 447 0 ‡ 0·13§  
Respiratory 434 3 (1%) 413 7 (2%) 3·03¶ (1·56 to 5·88) 0·0011  
Gastrointestinal 432 4 (1%) 412 9 (2%) 2·67¶ (1·37 to 5·20) 0·004  
Renal 434 1 (<1%) 414 3 (1%) 3·65 (1·96 to 6·82) <0·0001  
Admitted to hospital during follow-up 434 51 (12%) 416 48 (12%) 0·98 (0·65 to 1·47) 0·92  
Behavioural scale scores at 2 years assessed in strengths and difficulties questionnaire||  
Total difficulties 302 9·8 (4·9) 295 10·2 (4·9) 1·23 (0·85 to 1·78)**‡‡ 0·28  
Emotional problems 341 1·1 (1·2) 328 1·1 (1·2) 1·01 (0·61 to 1·67)**‡‡ 0·96  
Conduct problems 342 2·7 (1·8) 326 2·6 (1·8) 0·92 (0·65 to 1·31)**‡‡ 0·66  
Hyperactivity scale 334 4·2 (2·4) 315 4·5 (2·3) 1·10 (0·79 to 1·55)**‡‡ 0·57  
Peer problems scale 345 2·0 (1·7) 318 2·1 (1·6) 1·22 (0·88 to 1·69)**‡‡ 0·22  
Prosocial scale 339 6·3 (2·2) 320 5·9 (2·3) 1·20 (0·88 to 1·63)**‡‡ 0·25  
Impact scale 424 0·2 (1·0) 404 0·2 (1·2) 1·31 (0·73 to 2·35)**‡‡ 0·37  
EQ-5D  
Change in EQ-5D from baseline to birth 199 –0·023 (0·220) 191 –0·021 (0·207) 0·001§§ (–
0·034 to 0·036) 0·97  
Change in EQ-5D from baseline to 12 months 274 –0·015 (0·221) 279 –0·009 (0·213) 
0·003§§ (–0·026 to 0·032) 0·83  
Women’s views  
Women’s perception of treatment 1 month post-delivery (proportion extremely or fairly 
327 314 (96·0) 307 294 (95·6) 0·93 (0·42 to 2·04) 0·85 satisfied)  
*Hazard ratio (HR). †Median time to death: 759 days (range 1–1331) in the placebo group 
and 751 days (1–1335) in the progesterone group. ‡Regression failed with and without 
adjusting for previous pregnancy of more than 14 weeks. §Exact Fisher test. ¶Not adjusted 
for previous pregnancy of at least 14 weeks because regression failed. ||Mean age at 
assessment: 107·7 weeks (SD 17·7) in the placebo group and 106·9 weeks (17·1) in the 
progesterone group. **Score analysed as binary variable (raised compared with normal 
score). ‡‡Odds ratio (OR) of abnormal score. §§Mean difference.  
Table 4: Secondary outcomes  
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outcome after the prespecified adjustment for multiple comparisons (Bonferroni-Holm 
procedure): OR 0·86 (95% CI 0·61–1·22) for the obstetric outcome and OR 0·62 (0·38–1·03) 
for the neonatal outcome (table 2). Similarly, there was no effect on childhood outcomes 
(cognitive score 97·7 [SD 17·5] for placebo and 97·3 [17·9] for progesterone; difference in 
means –0·48, adjusted 95% CI –2·77 to 1·81).  
Among the components of the primary obstetric and neonatal outcomes, the proportion of 
babies with observed neonatal brain injuries on cerebral ultrasound scanning was lower in 
the progesterone group (18 [3%] of 584 vs 34 [6%] of 574; OR 0·50, 95% CI 0·31–0·84; table 
2). A reduction in brain injury was also observed in a sensitivity analysis restricted to 
participants in whom a neonatal brain scan was done (n=776; OR 0·54, 95% CI 0·32–0·88). 
Neonatal death was also less common in the progesterone group, but the low numbers 
precluded planned adjustment for the covariate previous pregnancy at 14 weeks or longer 
gestation.  
Similar results for primary outcomes were achieved in per-protocol analyses (687 [56%] of 
1226 patients in the intention-to-treat population; appendix); in analyses with multiple 
imputations of missing data on the primary outcomes (appendix); and in alternative 
multiple comparison procedures, including the Sidak-Holm method and permutation 
adjustment (50 000 permutations; data not shown). Comparison of characteristics of 
women included and not included in the per-protocol analysis are shown in the appendix. 
An additional sensitivity analysis with imputations for the variable smoking was done post 
hoc because of the difference in smoking prevalence in those with and without outcome 
data: again this generated similar results to the main analysis (data not shown). A post-hoc 
survival curve of time to death or delivery (primary obstetric outcome) showed that the 
differences between the progesterone and placebo groups appeared greatest at our 
prespecified gestational cutoff of 34 weeks (appendix).  
Rates of preterm birth were higher in the predefined subgroups of women with a positive 
fetal fibronectin test, women with a cervical length of at most 25 mm, and women with a 
cervical length of at most 15 mm (appendix). However, there were no significant 
interactions between these groups and the effect of progesterone on any of the obstetric, 
neonatal, or childhood outcomes. Within subgroups there was no significant effect of 
progesterone on any of the primary obstetric or childhood outcomes (table 3). The 
interaction term approached statistical significance (p=0·053) for the neonatal outcome in 
the subgroup with a history of a previous spontaneous preterm birth, in which the OR for 
the neonatal outcome was lower in the progesterone group (0·48, 95% CI 0·29–0·79) 
compared with the complementary group with no previous spontaneous preterm birth 
(1·22, 0·55–2·71). However, caution is needed in interpreting all these findings given the 
number of prespecified subgroup analyses undertaken on three primary outcomes.  
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Placebo group Progesterone group  
N n (%) or mean (SD)* N n (%) or mean (SD)*  
Pregnancy complications  
Maternal   
Obstetric cholestasis  589 6 (1%) 593 4 (1%)  
Hypertension  590 24 (4%) 593 23 (4%)  
Pre-eclampsia  590 11 (2%) 593 10 (2%)  
Eclampsia  590 1 (<1%) 593 0  
Preterm premature membrane rupture  590 72 (12%) 593 65 (11%)  
Antepartum haemorrhage  590 36 (6%) 593 37 (6%)  
Gestational diabetes  590 37 (6%) 593 27 (5%)  
Confirmed deep vein thrombosis  590 2 (<1%) 593 0  
Cervical cerclage  360 39 (11%) 368 41 (11%)  
Other maternal complication  590 164 (28%) 593 166 (28%)  
Fetal   
Any  590 18 (3%) 593 19 (3%)  
Abdominal circumference <5th percentile  18 4 (22%) 19 6 (32%)  
Liquor volume reduced  18 6 (33%) 19 6 (32%)  
Doppler >95th percentile (umbilical artery)  18 1 (6%) 19 1 (5%)  
Absent end diastolic flow (umbilical artery)  18 0 19 1 (5%)  
Reversed end diastolic flow (umbilical artery)  18 1 (6%) 19 1 (5%)  
Abnormal antenatal CTG  18 7 (39%) 19 3 (16%)  
Hospital admissions   
Antenatal hospital admissions per woman  
Mean (SD)  581 0·7 (1·3) 579 0·6 (1·1)  
Median (range)  581 0 (0–10) 579 0 (0–8)  
Hospital admissions for threatened preterm labour  581 132 (23%) 579 119 (21%)  
With tocolysis  581 18 (3%) 579 15 (3%)  
With steroid  581 71 (12%) 579 80 (14%)  
With antibiotic  581 52 (9%) 579 38 (7%)  
With cervical cerclage  581 10 (2%) 579 8 (1%)  
With magnesium sulfate  581 0 579 0  
Women with antenatal hospital admission for other 
reasons  
581 135 (23%) 579 107 (18%)  
Labour   
Duration of first stage (h)  463 4·1 (5·1) 470 4·3 (5·3)  
Duration of second stage (min)  
462 47·0 (132·8) 471 41·2 
(91·6)  
Duration of third stage (min)  465 17·0 (46·2) 477 16·1 (51·6)  
Artificial rupture of membranes performed  468 131 (28%) 448 122 (27%)  
Analgesia in labour (any)  576 455 (79%) 574 478 (83%)  
General anaesthetic  576 16 (3%) 574 12 (2%)  
Epidural  576 191 (33%) 574 197 (34%)  
Opiates  576 88 (15%) 574 88 (15%)  
Nitrous oxide  576 269 (47%) 574 303 (53%)  
Other  576 34 (6%) 574 31 (5%)  
Delivery method   
Spontaneous vaginal delivery  578 380 (66%) 576 375 (65%)  
LSCS in labour  578 58 (10%) 576 57 (10%)  
LSCS pre-labour  578 92 (16%) 576 84 (15%)  
Forceps  578 21 (4%) 576 27 (5%)  
(Table 5 continues on next page)  
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Placebo group Progesterone group  
N n(%)ormean(SD)* N n(%)ormean(SD)*  
Ventouse  578  18 (3%) 576  20 (3%)  
Vaginal breech (spontaneous or assisted)  578  9 (2%) 576  13 (2%)  
Blood loss (mL)  572  387 (356) 572  424 (394)  
Blood transfusion  578  10 (2%) 574  18 (3%)  
Antibiotics during labour and delivery  578  96 (17%) 573  92 (16%)  
Surgical procedure required  578  15 (3%) 575  18 (3%)  
Mean duration of hospital stay (days)  577  3·2 (2·2) 567  3·3 (4·1)  
Median duration of hospital stay, days (range)  577  3·0 (1·0–19·0) 567  3·0 (1·0–86·0)  
Any post-partum complication  580  83 (14%) 577  90 (16%)  
Placental examination     
No evidence of infection  84  57 (68%) 83  56 (67%)  
Chorioamnionitis  84  10 (12%) 83  9 (11%)  
Chorioamnionitis and funisitis  84  17 (20%) 83  18 (22%)  
Birth outcomes  
Outcomes at 2 years  
Male sex†  578  289 (50%)  578  293 (51%)  
Birthweight (g)  577  2822 (884)  577  2875 (847)  
Median Apgar score at 1 min (IQR)  553  9·0 (8·0–9·0)  557  9·0 (8·0–9·0)  
Median Apgar score at 5 min (IQR)  555  9·0 (9·0–10·0)  560  9·0 (9·0–10·0)  
Median length of hospital stay, days (IQR)  556  2·0 (1·0–6·0)  562  2·0 (1·0–4·0)  
 
Weight (kg)  355  13·2 (2·6)  332  13·4 (2·7)  
Height (cm)  369  87·2 (10·7)  347  87·4 (7·9)  
Head circumference (cm)  354  48·9 (4·6)  332  49·6 (6·7)  
*Data are n (%) or mean (SD), unless otherwise stated. Outcomes in the safety population 
(ie, women who took at least one tablet of placebo or progesterone). CTG=cardiotocograph. 
LSCS=lower segment caesarean section. †One baby of indeterminate sex in the 
progesterone group.  
Table 5: Safety outcomes  
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Most of the other secondary outcomes did not differ statistically between progesterone and 
placebo groups (table 4). Although neurodevelopmental impairments were similarly 
distributed in each group, somatic impairments in renal, gastrointestinal, and respiratory 
systems though of low frequency, were more common in the progesterone group. There 
were no apparent differences in the proportions with safety or other outcomes between 
the placebo and progesterone groups (table 5).  
Discussion  
OPPTIMUM is the largest randomised trial of vaginal progesterone for prevention of 
preterm birth in women at high risk. By contrast with published reports,13–15 we show no 
effect of progesterone on rates of either preterm birth or neonatal composite outcome. For 
the first time using a direct assessment, we provide strong evidence that the use of 
progesterone from 22–24 to 34 gestational weeks has no demonstrable effect on 2 year 
neurodevelopmental outcomes, either as cognitive scores or impairments, suggesting that 
progesterone prophylaxis to prevent preterm birth appears safe for the baby (at least up to  
2 years of age). Only one previous study has determined long-term effects of progestogens 
given to singleton pregnancies in a randomised trial of intramuscular 17α-
hydroxyprogesterone caproate,16,17 but this study used parent report and had a smaller 
sample size with a higher proportion lost to follow-up. The other published studies are 
restricted to questionnaire or health record-based assessments in twins whose mothers 
were enrolled in randomised trials of progesterone versus placebo.18,19  
OPPTIMUM was a pragmatic trial, set up to examine effects of progesterone on outcomes in 
a heterogeneous group of women at risk of preterm birth. We extended our recruitment 
criteria early in the study, when newly available information suggested we were missing 
women at high risk of preterm birth. Notably, the fibronectin- negative group recruited 
under the extended criteria, had rates of the primary outcome (death or preterm birth 
before 34 weeks) of 13% (appendix), some three times those of the background population 
of pregnant women in the UK.20 Hence, our decision to extend the recruitment criteria 
appears correct. Importantly, although we were able to define at baseline subgroups of 
women with higher rates of preterm birth (including those with a short cervix and those 
with a positive fibronectin test), our data suggest that the efficacy of progesterone (for all 
outcomes) is similar across groups. Therefore, our data do not support the premise that 
vaginal progesterone is specifically effective in women with a short cervix.  
Although we showed no overall effect, point estimates of the reduction in the odds of the 
obstetric outcome (0·86) and the neonatal composite outcome (0·62) are in the direction of 
benefit, but with CIs that show no advantage. Additionally, point estimates in the short 
cervix subgroups are similar to those reported in meta- analyses of the effect of 
progesterone in such women. For example, the OR for preterm birth prevention was 0·69 in 
OPPTIMUM, compared with a RR of 0·64 (before 34 weeks) in one systematic review 21 and 
a RR of 0·58 (before 33 weeks) in an individual patient data meta-analysis.1 The 
corresponding figures for effects on a neonatal composite are OR 0·54 in OPPTIMUM and RR 
0·57 in the individual patient data meta-analysis.1 An individual patient data meta-analysis, 
including the OPPTIMUM findings, to understand what the totality of evidence indicates, 
particularly within subgroups of interest, is likely to be helpful.  
Although we have shown no significant effect on the overall neonatal composite outcome, 
there appeared to be a reduction in neonatal brain injury. Progesterone-associated 
reduction in brain injury is plausible given supportive preclinical data in adult models 
showing potentially neuroprotective effects of reduced inflammatory cytokine production, 
reduced activation of microglial cells, and limited apoptosis,22,23 although a recent trial of 
over 1000 adult participants with traumatic brain injury has shown no clinical therapeutic 
effect.24 However, in the absence of long-term improvements in cognitive function,  
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a protective effect of progesterone on brain injury (defined by ultrasound) might not be 
important clinically: not only was brain injury on ultrasound a relatively rare event in 
OPPTIMUM but other studies have shown no correlation between this finding and longer 
term neurosensory impairment.25 Additionally, these non-significant red- uctions in the 
neonatal composite adverse outcome need to be considered against the non-significant 
increase in the childhood adverse outcome of death or moderate-to-severe 
neurodevelopmental impairment.  
OPPTIMUM strongly suggests that the efficacy of progesterone in improving outcomes is 
either non- existent or weak. Given the heterogeneity of the preterm labour syndrome we 
cannot exclude benefit in specific phenotypic or genotypic subgroups of women at risk. 
However, the subgroups of women who might benefit do not appear to be easily 
identifiable by current selection strategies, including cervical length measurement and 
fibronectin testing.  
Reassuringly, our study suggests that progesterone is safe for those who wish to take it for 
preterm birth prophylaxis. The overall rate of maternal or child adverse events was similar 
in the progesterone and placebo groups. There were few differences in the incidence of 
adverse secondary outcomes in the two groups, with the exception of a higher rate of renal, 
gastrointestinal, and respiratory complications in childhood in the progesterone groups. 
Importantly, the absolute rates of these complications was low. Follow-up of other babies 
exposed in utero to vaginal progesterone would be helpful in determining whether the 
increased rate of some renal, gastrointestinal, and respiratory complications is a real effect 
or a type I error.  
A potential weakness in our trial is that overall compliance was only 69%. This contrasts 
with a reported compliance of 88·5% in the study by Hassan and colleagues,13 but is greater 
than the compliance seen in routine clinical practice.26 Additionally, the assumption in the 
Hassan study that women who did not return study medication were fully compliant might 
have erroneously inflated their estimate of compliance. No information on compliance was 
reported in the other large study on vaginal progesterone in singletons.15 Notably, in 
OPPTIMUM, the effect size for each of the primary outcomes was very similar in the per-
protocol analysis (restricted to those with adequate treatment compliance) compared with 
the intention-to-treat group, suggesting that suboptimum compliance did not have a major 
effect on overall results.  
We believe that OPPTIMUM should prompt a major review of the use of progesterone for 
preterm birth prophylaxis, a search to identify specific women who might specifically 
benefit, and a redoubling of efforts to find alternative strategies to prevent preterm birth in 
women at risk. For those clinicians and women who wish still to use progesterone for 
preterm birth prophylaxis, our data provide reassurance that it appears safe, at least until 2 
years of age of the child.  
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